Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Apr 24, 2026; 17(4): 119365
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.119365
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.119365
Construction and validation of a multiparameter diagnostic model based on conventional tumor markers and cytokines for lung cancer
Yi-Ning Zhang, Hui-Juan Wang, Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing 100020, China
Tao Jiang, Division of Medicine Innovation Research, Chinese PLA General Hospital, Beijing 100853, China
Peng-Jun Zhang, Department of Interventional Therapy, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China
Co-first authors: Yi-Ning Zhang and Tao Jiang.
Co-corresponding authors: Peng-Jun Zhang and Hui-Juan Wang.
Author contributions: Wang HJ and Zhang PJ designed the study and they contribute equally to this study as co-corresponding authors; Jiang T, Zhang PJ and Wang HJ performed the research; Jiang T and Zhang YN analyzed the data; Wang HJ wrote the paper; Zhang PJ and Wang HJ revised the manuscript for final submission; Zhang YN and Jiang T contribute equally to this study as co-first authors.
Supported by the National Key Research and Development Program of China, No. 2020YFC2004604.
Institutional review board statement: The study was reviewed and approved by the Peking University Cancer Hospital & Institute Review Board (Approval No. 2023KT37).
Informed consent statement: This study was approved by the Ethics Committee with a waiver of informed consent.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: There were no data to share.
Corresponding author: Hui-Juan Wang, MD, Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, No. 8 Gongti South Road, Beijing 100020, China. 13466791738@163.com
Received: January 30, 2026
Revised: February 10, 2026
Accepted: March 6, 2026
Published online: April 24, 2026
Processing time: 81 Days and 1.4 Hours
Revised: February 10, 2026
Accepted: March 6, 2026
Published online: April 24, 2026
Processing time: 81 Days and 1.4 Hours
Core Tip
Core Tip: We aimed to evaluate the diagnostic value of conventional tumor markers and cytokines and construct a multiparameter diagnostic model. After four multiparameter joint analysis methods analysis, a model that included carcinoembryonic antigen, cytokeratin 19 fragment, interleukin-8 and tumor necrosis factor-alpha for the detection of lung cancer was built and validated. It may provide more comprehensive theoretical support for the diagnosis and targeted therapy of lung cancer.